SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today that Dr. Richard Colonno, the company’s Chief Scientific Officer, would be presenting data on their hepatitis C virus NS5A inhibitor program at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark (April 22-26, 2009). Dr. Colonno will be presenting new data on several series of potent NS5A inhibitors in a poster entitled Identification and Profile of Potent and Selective Inhibitors of HCV NS5A Protein - Poster #875, Saturday April 25, 2009.
